How were RXi Pharmaceuticals' earnings last quarter?

RXi Pharmaceuticals Co. (NASDAQ:RXII) announced its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.02 million. RXi Pharmaceuticals had a negative net margin of 4,990.20% and a negative trailing twelve-month return on equity of 412.15%.

When did RXi Pharmaceuticals' stock split?

RXi Pharmaceuticals's stock reverse split on the morning of Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of RXi Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RXi Pharmaceuticals investors own include Rigel Pharmaceuticals (RIGL) , Novavax (NVAX) , Auris Medical (EARS) , Endologix (ELGX) , Idera Pharmaceuticals (IDRA) , Synergy Pharmaceuticals (SGYP) , Anavex Life Sciences (AVXL) , Micron Technology (MU) and

NASDAQ:RXII

RXi Pharmaceuticals (RXII) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free RXII Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.60
▼
$0.64
50-Day Range: $0.36
▼
$0.50
52-Week Range: $0.31
▼
$7.70

Volume: 61,688 shs
Average Volume: 1.73 million shs
Market Capitalization: $2.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get RXi Pharmaceuticals alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About RXi Pharmaceuticals Stock (NASDAQ:RXII)

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

Find out more here >>>

RXII Stock News Headlines

October 26, 2023 | finance.yahoo.com

Rex International Holding Ltd (RXI.SG)

April 19, 2023 | thestreet.com

Galena's Breast Cancer Vaccine Doomed to Fail

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 20, 2023 | finance.yahoo.com

Q4 2022 Catalyst Pharmaceuticals Inc Earnings Call

September 30, 2022 | finance.yahoo.com

iShares Global Consumer Discretionary ETF (RXI)

See More Headlines

Receive RXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/14/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RXII
CUSIP: N/A
CIK: 1533040
Web: www.rxipharma.com
Phone: (508) 767-3861
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($4.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,450,000.00
Net Margins: -4,990.20%
Pretax Margin: N/A
Return on Equity: -412.15%
Return on Assets: -179.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.77
Quick Ratio: 1.77

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 279.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.77 per share
Price / Book: 0.83

Miscellaneous

Outstanding Shares: 4,380,000
Free Float: N/A
Market Cap: $2.79 million
Optionable: Not Optionable
Beta: 2.07

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Gerrit Dispersyn
President, Chief Executive Officer & Director
James Cardia
Vice President-Business Operations
Caitlin Kontulis
Secretary, VP-Finance & Administration
Simon Fricker
Vice President-Research

Key Competitors

View All Competitors

RXII Stock Analysis - Frequently Asked Questions

How were RXi Pharmaceuticals' earnings last quarter?: RXi Pharmaceuticals Co. (NASDAQ:RXII) announced its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.02 million. RXi Pharmaceuticals had a negative net margin of 4,990.20% and a negative trailing twelve-month return on equity of 412.15%.
When did RXi Pharmaceuticals' stock split?: RXi Pharmaceuticals's stock reverse split on the morning of Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of RXi Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other RXi Pharmaceuticals investors own include Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Auris Medical (EARS), Endologix (ELGX), Idera Pharmaceuticals (IDRA), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Micron Technology (MU) and

This page (NASDAQ:RXII) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

RXi Pharmaceuticals (RXII) Stock Price, News & Analysis

About RXi Pharmaceuticals Stock (NASDAQ:RXII)

RXII Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

RXII Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info